REGN Maintained by Piper Sandler -- Price Target Raised to $865

gurufocus.com · 2026-10-19

Regeneron Pharmaceuticals (REGN) Analyst Rating Update On October 19, 2026, Piper Sandler maintained an "Overweight" rating for Regeneron Pharmaceuticals (RE

TickrTrends take: Piper Sandler's price target increase to $865 for Regeneron Pharmaceuticals occurs within a context where TickrTrends currently assesses the company as fairly valued in the Healthcare sector. This analyst action suggests confidence in REGN's prospects, though the fairly valued designation indicates the market may already be pricing in meaningful growth expectations. Investors focused on valuation metrics should monitor whether upcoming results or pipeline developments alter the current equilibrium between stock price and intrinsic value.

Read the full story at gurufocus.com →